摘要
目的探讨血栓通治疗冠心病心绞痛的临床疗效及其安全性。方法选取宜春市第二人民医院2017年3月—2018年8月收治的冠心病心绞痛患者98例,随机分为对照组和观察组,各49例。对照组给予常规治疗,观察组给予血栓通治疗。比较两组临床疗效,治疗前后全血黏度(BV)、血浆黏度(SV)和纤维蛋白原(FB)、三酰甘油(TG)、总胆固醇(TC),并观察两组不良反应发生情况。结果观察组总有效率高于对照组(P<0.05)。治疗前两组BV、SV、FB、TG、TC比较,差异无统计学意义(P>0.05);治疗后观察组BV、SV、FB、TG、TC低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论血栓通治疗冠心病心绞痛的临床疗效确切,可控制血流和血脂指标,且安全性较高。
Objective To investigate the clinical efficacy and safety of Xueshuantong in the treatment of angina pectoris of coronary heart disease.Methods A total of 98 cases of patients with angina pectoris were selected from March 2017 to August 2018 in the Second People's Hospital of Yichun City,which were randomly divided into control group and observation group,with 49 cases each.The control group was given routine treatment,the observation group was given Xueshuantong treatment.Before and after treatment,the whole blood viscosity(BV),plasma viscosity(SV),fibrinogen(FB),triglyceride(TG)and total cholesterol(TC)were compared.Results The total effective rate of the observation group was higher than the control group(P<0.05).Before treatment,there was no significant difference in BV,SV,FB,TG and TC between the two groups(P>0.05);after treatment,BV,SV,FB,TG andifference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of Xueshuantong in the treatment of angina pectoris of coronary heart disease is accurate,it can control blood flow and blood lipid index,and with high safety.
作者
易丽
汪群
YI Li;WANG Qun(The Second People's Hospital of Yichun City,Yichun 336000,China)
出处
《临床合理用药杂志》
2020年第18期11-13,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
冠心病
心绞痛
血栓通
治疗结果
Coronary disease
Angina pectoris
Xueshuantong
Treatment outcome
